Latest studies
- RecruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
Diffuse Cutaneous Systemic SclerosisAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionAustria - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
This study looks at a new drug, epcoritamab, combined with standard medicines (R2) for adults with follicular lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this new combination is.
Follicular Lymphoma (FL)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
This study looks at how safe a medicine called KVD900 is when used long-term for swelling attacks in people with Hereditary Angioedema (HAE) Type 1 or 2. It also checks how the body handles the medicine in teenagers.
Hereditary Angioedema Type I or IIAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
This study looks at a treatment called plasma exchange with human albumin for people with serious liver problems. We want to see if this treatment helps people live longer and get better, compared to standard care alone.
Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalizationAustria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study with healthy volunteers to investigate the safety, tolerability, blood concentration and some effects of various amounts of the pharmaceutical substance SR-878
This study is looking for healthy volunteers to test a new medicine called SR-878. Researchers want to see if it's safe, how well people tolerate it, and how much of it stays in the blood. They'll also check for any early effects.
Healthy VolunteersAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Pulmonary Arterial Hypertension (PAH)Austria - Ongoing, recruitingTherapeutic use (Phase IV)
A prospective, randomized, double-blind, controlled trial on the application of a 10%-lidocain spray prior to the insertion of a peripheral intra-venous catheter in female adults
This study looks at whether a numbing spray can reduce pain when putting in an IV drip (a small tube in your vein) in adult women. We're hoping to find a simple way to make this common procedure less uncomfortable.
PainAustria - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
Microsatellite Instability High (MSI-H) or Mismatch Repair DeficientMetastatic Colorectal Cancer (dMMR)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217.
This study looks at whether a blood test called ctDNA can help doctors decide on treatment for people with stage II bowel cancer. It compares giving chemotherapy based on this test to just watching and waiting, to see which approach leads to better outcomes.
colon cancer stage II, rectal cancer stage IIAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS"
This study looks at the long-term safety of a medicine called Cendakimab (also known as CC-93538) for adults with a condition called Eosinophilic Esophagitis. It checks for side effects over a long period to make sure the treatment is safe for people to use.
Eosinophilic esophagitisAustria - Recruiting
The Medacta International SMS Post-Marketing Surveillance Study
This study looks at a new hip replacement part called the SMS femoral stem. It follows people aged 18-75 in the UK who have a total hip replacement due to severe hip pain from conditions like arthritis, to see how well the new part works over time.
ArthrosisTraumatic ArthritisRheumatoid PolyarthritisCongenital Hip DysplasiaAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients
This study looks at a medicine called Calquence for older or weaker patients with a type of blood cancer called CLL. It's for people who haven't had treatment before or whose cancer has come back. We want to see how well the medicine works after about six months.
treatment-naïve or relapsed/refractory chronic lymphocytic leukemiaAustria - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerAustria - Active not recruitingPHASE3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study looks at new drug combinations for advanced lung cancer. It compares a new drug (Datopotamab Deruxtecan) with an existing treatment (Pembrolizumab) and chemotherapy, to see if the new combinations are safer and work better.
Metastatic Non Small Cell Lung CancerAustria - Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
Diffuse Large B-cell LymphomaAustria - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This study is looking into a new treatment called prasinezumab for people in the early stages of Parkinson's disease. Researchers want to see if it's safe and helps improve symptoms. Participants will either receive the new medicine or a dummy treatment, called a placebo.
Parkinsons DiseaseAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaAustria - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
This study is looking at a new medicine called Avapritinib for children and young people with certain types of solid tumours. It aims to find the right dose, see how safe it is, and if it can help shrink or control the cancer. It's an early-stage study to understand the drug better.
Solid Tumors Dependent on KIT or PDGFRA SignalingAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisAustria - Active not recruitingPHASE2, PHASE3
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain tumour, in children and young people. It aims to find the best treatments based on the tumour's specific characteristics, hoping to improve the chances of recovery with fewer side effects.
Brain TumorsAustria - Active not recruitingPHASE2
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
This study is looking into the long-term safety and effects of a medicine called Votoplam for people with Huntington's disease. Participants who were already in a previous study with Votoplam will continue to take it to see how it works over a longer time.
Huntington DiseaseAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
This study is testing a new treatment combination for locally advanced cervical cancer. It compares standard chemotherapy and radiation with the same treatment plus a new drug, pembrolizumab (Keytruda), to see if it helps patients live longer and stops the cancer from growing.
Locally Advanced Cervical CancerAustria - Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
This study looks at how well a medicine called Atezolizumab works and how happy people are with it when used for lung cancer or a type of liver cancer in normal NHS care. It also checks for side effects.
Lung Cancer, Hepatocellular CarcinomaAustria - Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
This registry tracks new adult cases of a rare cancer called Epithelioid Hemangioendothelioma (EHE). It aims to better understand the disease, its progression, and how different treatments work, by collecting information from patients across Europe and the UK.
Epithelioid HemangioendotheliomaSarcoma,Soft TissueAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Austria - Active not recruiting
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
This study looks at how well a medicine called inclisiran works for people with high cholesterol and helps prevent heart problems. We want to see if it lowers bad cholesterol and if people stick to taking it as part of their usual care.
Primary HypercholesterolemiaMixed DyslipidemiaAustria - Active not recruitingNA
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
This study looks at the best time to have surgery for advanced ovarian cancer. It compares having surgery first, then chemotherapy, versus having some chemotherapy first, then surgery, then more chemotherapy, to see which approach works better.
Ovarian CancerAustria - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.
This study looks at a new medicine called cabozantinib for young people with a type of bone cancer called osteosarcoma. It compares cabozantinib plus supportive care with supportive care alone to see if it helps stop the cancer from growing.
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults, OsteosarcomaAustria - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, TAK-676, for adults with advanced solid cancers. It aims to see if TAK-676 is safe, how well it's tolerated, and how it works, both alone and with another cancer drug called Pembrolizumab (Keytruda).
Solid NeoplasmAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
This study looks at a new medicine called depemokimab for severe asthma with high eosinophils. It compares it to existing treatments like mepolizumab and benralizumab over a year to see if it's just as good at preventing asthma attacks and improving control.
Severe asthma with an eosinophilic phenotypeAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
This study is testing a new inhaled powder medicine for a lung condition called pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients and if it's safe. It compares different strengths of the new medicine against a dummy powder.
Pulmonary Arterial HypertensionAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaAustria - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular CarcinomaAustria - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia AAustria - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Austria - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerAustria - Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
This study looks at how well a drug called VITRAKVI works and how safe it is for people with TRK fusion cancer. This type of cancer happens when certain genes fuse together. Doctors want to see how VITRAKVI helps patients in real-world use.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionAustria - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryAustria - RecruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaAustria - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCAustria - AuthorisedTherapeutic confirmatory (Phase III)
High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial
This study looks at using strong steroid medicines to treat a type of stroke in children called focal cerebral arteriopathy (FCA). Researchers want to see if these medicines can reduce the inflammation in blood vessels and improve children's recovery.
Focal cerebral arteriopathy and childhood strokeFocal cerebral arteriopathy (FCA) is an inflammatory vessel wall diseaseprovoked by infection.Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria
This study is looking at a new drug, balcinrenone, given with an existing drug, dapagliflozin (Forxiga), for people with long-term kidney disease and too much protein in their urine. It aims to see if this new combination helps protect the kidneys.
Chronic Kidney Disease and AlbuminuriaAustria - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura
This study is testing a new way to treat a rare blood disorder called TTP. It looks at whether a medicine called Cablivi, along with other treatments, can help people with TTP get better without needing a common but intensive procedure called plasma exchange.
Thrombotic Thrombocytopenic PurpuraAustria